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Manic Fringe deficiency imposes Jagged1 addiction
to intestinal tumor cells
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Delta ligands regulate Notch signaling in normal intestinal stem cells, while Jagged1 activates
Notch in intestinal adenomas carrying active β-catenin. We used the ApcMin/+ mouse model,
tumor spheroid cultures, and patient-derived orthoxenografts to address this divergent
ligand-dependent Notch function and its implication in disease. We found that intestinal-
specific Jag1 deletion or antibody targeting Jag1 prevents tumor initiation in mice. Addiction
to Jag1 is concomitant with the absence of Manic Fringe (MFNG) in adenoma cells, and
its ectopic expression reverts Jag1 dependence. In 239 human colorectal cancer patient
samples, MFNG imposes a negative correlation between Jag1 and Notch, being high Jag1
in the absence of MFNG predictive of poor prognosis. Jag1 antibody treatment reduces
patient-derived tumor orthoxenograft growth without affecting normal intestinal mucosa.
Our data provide an explanation to Jag1 dependence in cancer, and reveal that Jag1–Notch1
interference provides therapeutic benefit in a subset of colorectal cancer and FAP syndrome
patients.
DOI: 10.1038/s41467-018-05385-0 OPEN
1 Cancer Research Program. CIBERONC. Institut Mar d’Investigacions Mèdiques, Hospital del Mar, Doctor Aiguader 88, 08003 Barcelona, Spain.
2 Department of Discovery Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. 3 Research Program on Biomedical Informatics,
IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor Aiguader 88, 08003 Barcelona, Catalonia, Spain. 4 Department of
Translational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. 5Department of Pathology, Hospital del Mar, Doctor Aiguader
88, 08003 Barcelona, Spain. 6 Universitat Autonoma of Barcelona, Barcelona 08193, Spain. 7 Department of Oncology, Hospital del Mar, CIBERONC. Doctor
Aiguader 88, 08003 Barcelona, Spain. 8 Laboratori de Recerca Translacional, IDIBELL-Institut Català d’Oncologia Gran Via km 2.7, Hospitalet, 08907
Barcelona, Spain. These authors contributed equally: Erika López-Arribillaga, Verónica Rodilla. Correspondence and requests for materials should be
addressed to A.B. (email: abigas@imim.es) or to C.W.S. (email: siebel.christian@gene.com) or to L.E. (email: lespinosa@imim.es)









As the second leading cause of cancer-related deaths inWestern populations, colorectal cancer (CRC) requires adeeper mechanistic understanding to fuel new therapeutic
approaches. A series of well-characterized genetic alterations
provide a framework to explain progression from adenoma to
invasive CRC. In particular, human and mouse genetics identified
inactivation of the adenomatous polyposis coli (Apc) tumor
suppressor as an essential early event1,2. Apc loss activates Wnt/
β-catenin that critically regulates intestinal stem cells (ISCs)3,4
and tumor initiation5. Germline mutations in the Apc gene cause
the inherited familial adenomatous polyposis (FAP) syndrome6–9,
which typically manifests with spontaneous polyp growth in the
mid-teen years, progressing to more than a hundred adenoma-
tous colon polyps by the age of 35. CRC ensues unless FAP
patients undergo prophylactic colectomy. The best-characterized
model for intestinal polyp formation is the ApcMin/+ mouse. Like
FAP patients, these mice develop early (4–5 weeks of age) mul-
tiple adenomas, mainly in the small intestine, with death ensuing
after 4–8 months10–12. Progression from intestinal adenoma to
advanced CRC, both in mice and humans, correlates with the
accumulation of specific mutations and aberrant signaling
through additional pathways13.
The Notch pathway is an evolutionarily conserved signal for
cell–cell communication, controlling lineage decisions in myriad
tissues. Mammalian Notch signaling relies on four receptors
(Notch1–4) and ligands of the Delta (Dll1, 3, and 4) or Jagged
(Jag1 and 2) families. Receptor–ligand interactions are regulated
by receptor glycosylation, with the Fringe family of N-acet-
ylglucosaminyltransferases, mainly Lunatic Fringe (LFNG) and
Manic Fringe (MFNG), potentiating Delta-induced signals and
reducing responsiveness to Jagged ligands14–17. Interactions
between Notch receptors and ligands, typically expressed on
neighboring cells, trigger sequential proteolytic cleavages cata-
lyzed by ADAM18 proteases and the gamma-secretase complex19.
The subsequently liberated intracellular domain of Notch (ICN)
translocates to the nucleus and, together with RBPJ, activates
transcription of target genes, often including members of the Hes
family of transcriptional repressors20,21. Lineage studies in the
mammalian intestine provide a paradigm for mammalian Notch
signaling. Notch1 and Notch2, expressed on the crypt base
columnar (CBC) stem cells, pair with Dll1 and Dll4, expressed on
neighboring Paneth cells, to control cell proliferation and pro-
mote absorptive over secretory fates22–24. Pharmacological or
genetic inhibition of Notch in the intestinal epithelium results in
loss of the proliferative crypt compartment and replacement of
intestinal stem and progenitors cells with post-mitotic secretory
cells25. Notch not only induces expression of transcriptional
repressors such as Hes1 to prevent stem and progenitor cell dif-
ferentiation, but also induces transcription of several ISC genes
such as Olfm426 and Bmi127.
Collaborating Notch and Wnt signals control cell proliferation
and fate in the normal crypt and have been linked to intestinal
cancer, with Notch functioning downstream or in parallel with β-
catenin28,29. Adenomas generated in Apc mutant mouse models
display active Notch signaling and have been reported to be
sensitive to gamma-secretase inhibitors (GSIs), which partially
induce adenoma differentiation into post-mitotic goblet cells25.
We previously identified Jag1–Notch signaling as an important
link between Wnt and intestinal cancer, with Jag1 as both a
transcriptional target of β-catenin and a Notch signal inducer in
Apc-mutant adenomas. Importantly, Jag1 haploinsufficiency
correlated with decreases in adenoma size and cell proliferation29.
Differential usage of Notch ligands has been associated with
expression of Fringe glycosyltransferases. In drosophila, Fringe
was identified as a modifier of Notch receptor that favored the
interaction with Delta and prevented the one with Serrate (Jag
ortholog)30. However, the molecular mechanisms supporting the
differential use of Dll and Jag ligands in normal and transformed
intestinal epithelial cells, respectively, remain completely unex-
plored. Using mouse genetic models, therapeutic antibodies, and
organoid/tumor spheroid models, we now show that epithelial
Jag1 is specifically required for tumor initiation, stem cell marker
expression, and stem cell activity of the adenoma cells, both
in vitro and in vivo. Furthermore, addiction of adenoma cells to
Jag1 is mediated by MFNG. In agreement with this, JAG1 levels
predict patient prognosis specifically in the group that carries
MFNG-negative tumors.
Results
Intestinal epithelial Jag1 deletion blocks tumor initiation. We
previously reported that heterozygous deletion of Jag1 reduced
adenoma cell proliferation and tumor size in ApcMin/+ mice
without affecting tumor number29. To determine whether
intestine-specific Jag1 deletion would be sufficient to affect ade-
noma growth or number, we functionally deleted both copies of
Jag1 in ApcMin/+ mice by crossing the Jag1lox/lox strain31 with
Villin-Cre deleter mice32. A ROSA26-YFP reporter confirmed
Cre activity in all intestinal epithelial cells, including CBC cells
intermingled with Paneth cells33 and the quiescent ISCs at the +4
position (Supplementary Fig. 1A). Although Villin-Cre is active as
early as embryonic day 12.532, intestinal Jag1 deletion did not
affect growth (Supplementary Fig. 1B), impact intestinal integrity
or alter the distribution of cell lineages (Supplementary Fig. 1C),
consistent with observations in adult intestines following Jag1
deletion34. In contrast, in the ApcMin/+ background, approxi-
mately four-fold fewer tumors arose following Jag1 homozygous
deletion compared to Jag1 wild-type (WT) (p= 0.0016) or het-
erozygous deletion (HT) (p= 0.038), respectively (Fig. 1a, b).
These results are different to those obtained using the general
Jag1 heterozygous mice and indicate that epithelial Jag1 is
required for tumor initiation. However, Jag1 expressed in the
stroma of the tumor may also contribute to different aspects of
tumor initiation and progression, as suggested from our previous
work29. YFP expression (Supplementary Fig. 1D) and the absence
of functional Jag1 mRNA in YFP+ cells from the rare tumors in
Jag1lox/lox mice (Supplementary Fig. 1E) confirmed effective Jag1
exon 4 deletion. In the composite ApcMin/+ mice, most Jag1 WT
adenomas showed high levels of nuclear ICN1 (Fig. 1c) and total
and nuclear Notch2 (Supplementary Fig. 1F) mainly restricted to
the epithelial component, compared to the levels detected in
tumors lacking Jag1. Further supporting the notion that Jag1
deletion inhibited Notch activity, we observed decreased expres-
sion of the Notch target genes Hes1, c-Myc, and Nrarp in Jag1
knockout (KO) compared to WT tumors (Fig. 1d). Such
decreased Notch activity correlated with reduced tumor cell
proliferation, as assessed using Ki67 staining (Fig. 1c). However,
we did not detect a significant increased in the number of
cleaved-caspase 3-positive cells (apoptotic) in any Jag1 genotype
(Supplementary Fig. 1G). In addition, ApcMin/+ mice carrying the
different Jag1 genotypes showed a comparable distribution of
dysplastic crypts, tubular and villous adenomas (Supplementary
Fig. 1H), indicating that Jag1 requirement is not restricted to any
particular tumor subtype.
Next, we exploited a potent and selective antibody antagonist
targeting Jag135 to ask whether pharmacologic Jag1 inhibition
would interfere with adenoma formation or growth in vivo. We
began treating ApcMin/+;Villin-Cre mice at 8 weeks of age, when
some intestinal polyps have already been formed, with isotype
control antibody or anti-Jag1 blocking antibody (Fig. 1e). After
10 weeks of weekly treatment, selective Jag1 blockade significantly
reduced the number of polyps in the small intestine (SI) and
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Fig. 1 Jag1 is required for tumor initiation and tumor-associated Notch signaling. a Intestine Swiss-roll images from representative ApcMin/+;Jag1 wild-type
(Jag1+/+) or knockout (Jag1lox/lox) mice obtained with the stereomicroscope. Red arrowheads denote intestinal tumors. b Quantification of tumor number
per Swiss-roll section in the indicated genotypes analyzed at 2.5–3 months of age. c IF or IHC analysis of two representative ApcMin/+;Jag1+/+ or Jag1lox/lox
adenomas showing the levels of active Notch1 (ICN1) and c-Myc, and the proportion of proliferating cells determined by Ki67 staining. d qRT-PCR analysis to
determine the mRNA levels of the indicated Notch targets in tumors from different genotypes relative to β2-microglobulin. e ApcMin/+;Villin-Cre mice were
dosed weekly for 10 weeks with 10mg per kg of either isotype control (black in f) or anti-Jag1 blocking antibodies (red in f) starting at 8 weeks of age (n= 5
per treatment group), near the onset of polyp formation. f, g Number of polyps that grew in total (p= 0.0175), in the small intestine (SI) (p= 0.025), where
most polyps arise in this model, or in the colon (CO) (f) and analysis of polyp size in the same experiment (g). h Overall survival analysis in separate cohorts
of 10 animals per treatment group that received weekly doses beginning at 8 weeks of age. Bars represent mean values ± standard error of the mean (s.e.m.);
p values were derived from an unpaired t-test, two-tailed (*p < 0.05, **p < 0.01, and ***p < 0.001). Scale bars represent 75 μm
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almost precluded the formation of colonic (CO) tumors (Fig. 1f),
with no detectable signs of systemic toxicity. Intriguingly, in anti-
Jag1-treated animals, small tumors (< 2.5 mm) were essentially
undetectable (Fig. 1g), while no difference was observed with
larger tumors. These data are consistent with our genetic results,
bolstering the notion that antibody treatment completely
precludes polyp initiation induced by Apc mutations. In contrast,
it did not affect the growth of well-established polyps present
at the start of treatment. Importantly enough, overall survival
trended longer following anti-Jag1 treatment (Fig. 1h), although
the effect was not statistically significant.
Together, these results indicate that Jag1 is not essential for
normal intestinal homeostasis, but it is required for β-catenin-
driven adenoma formation. Thus, genetic deletion of epithelial
Jag1 or systemic inhibition using a blocking antibody is sufficient
to prevent adenoma formation in the ApcMin/+ mice, with no
evident signs of toxicity.
Jag1-deficient adenomas reduce stem cell gene transcription.
To explore the mechanism by which Jag1 deletion or inhibition
impacts adenoma formation, we compared the expression levels
of several stem cell markers in the Jag1 KO versus WT adenomas.
Supporting a role for Jag1 in adenoma formation and by exten-
sion in tumor-initiating cell (TIC) activity, Jag1 KO adenomas
expressed reduced levels of Lgr5, Bmi1, Ephb2, c-Myc, Sox9, and
Cd133 compared to the Jag1 WT, as determined by qRT-PCR
(Fig. 2a) and in situ hybridization (ISH) (Fig. 2b, c). Immuno-
fluorescence (IF) analysis of endogenous LGR5 protein confirmed
that this particular stem cell-like tumor population was reduced
in the Jag1 KO mice (from 48 in the WT to 21% in average),
whereas the ISC compartment of normal crypts remained unaf-
fected (Fig. 2d). We also determined the expression levels of the
intestinal differentiation markers in these adenomas. We found
that presence of Paneth cell in the tumors, as determined by
lysozyme (Lyz1) detection, negatively correlated with the number
of functional Jag1 alleles, being KO tumors more frequently
Lyz1 positive (70%) compared to HT (40%, p < 0.05) or WT
(20%, p < 0.01) tumors (Fig. 2e). In contrast, expression of the
absorptive marker carbonic anhydrase II (CAII) was virtually lost
in the Jag1 KO tumors (p < 0.01, compared to the WT tumors).
These results suggest that Notch signaling through Jag1 promotes
stemness specifically in the intestinal adenomas while preventing
differentiation toward the secretory lineage.
Jag1 is required for tumor spheroid growth in vitro. We
functionally assayed whether Jag1-induced Notch signaling reg-
ulates TIC activity of intestinal adenomas by using the well-
established model of 3D cultures that allows the maintenance of
tissue-specific stem cells. In particular, we isolated Jag1 WT or
KO adenoma cells from ROSA26-YFP;ApcMin/+ mice (Fig. 3a)
and seeded under standard culture conditions for organoid and
tumor/adenoma spheroids24,36–39. In three independent experi-
ments, we obtained 70–80 adenoma spheroids per well from
50,000 isolated YFP+ Jag1 WT cells seeded, in contrast with the
Jag1 KO adenoma cells that completely failed to form spheroids
(Fig. 3b). As expected, Jag1 WT spheroids grew as secondary
spheroids and after subsequent passages with comparable
potential (not depicted), reflecting their stem cell activity.
Treatment with the GSI DAPT inhibited growth of primary and
secondary spheroids (Supplementary Fig. 2A), consistent with
growth depending on Notch signaling. ApcMin/+ adenoma cells
growing as three-dimensional (3D) structures displayed high
protein levels of the ISC markers Lgr5, Bmi1, Cd44, and Ephb2,
as well as Jag1 with rare cells expressing the intestinal differ-
entiation markers Muc2, synaptophysin, CAII, and lysozyme
(Supplementary Fig. 2B), in contrast to the non-transformed
organoid structures (Supplementary Fig. 2C). To further study
the mechanisms underlying Jag1 dependence in this model, we
generated the composite murine line ApcMin/+;Jag1lox/lox;β-actin-
Cre-ERT, in which deletion of exon 4 of Jag1 can be induced with
4-OH tamoxifen resulting in a non-functional JAG1 protein. In
the absence of 4-OH tamoxifen, spheroids derived from these
adenoma cells grew similarly to those derived from the standard
ApcMin/+ strain. Treatment with 5 μM 4-OH tamoxifen pre-
vented spheroid growth when supplied at the beginning of the
culture (not depicted), and eradicated preformed ApcMin/+;
Jag1lox/lox;β-actin-Cre-ERT spheroids after 3–4 days of treatment
(Fig. 3c). In contrast, 4-OH tamoxifen treatment did not affect
Jag1lox/+ (Fig. 3c) or Jag1+/+ spheroids (not depicted). Treatment
with 4-OH tamoxifen for 24–48 h decreased ICN1 levels even in
the presence of Dll4 (Supplementary Fig. 2D), and led to a
reduction in the mRNA levels of the Notch targets Hes1, Nrarp,
and c-Myc, and the stem cell markers Ephb2, Bmi1, Hopx, Lrig1,
and mTert (Fig. 3d). By IF analysis, we found that 4-OH
tamoxifen treatment diminished the number of proliferating
Ki67-positive cells and increased the quantity of lysozyme-
(Paneth) and Alcian Blue-positive (mucosecretory) cells without
significantly affecting CAII levels (Fig. 3e–g). These changes
correlated with an increase in the number of apoptotic cells, as
determined by active-caspase 3 staining at 48 h after 4-OH
tamoxifen treatment closely resembling the effects of Notch
inhibition by DAPT (Fig. 3e). Interestingly, active-caspase 3 and
Alcian blue stainings were both detected in cells delivered into
the spheroid lumen suggesting that Notch inactivation following
Jag1 deletion imposes the terminal mucosecretory differentiation
of adenoma cells leading to cellular apoptosis. Similarly, treat-
ment of ApcMin/+ spheroids for 72 h with the antibody targeting
Jag1 reduced cell viability when compared with the antibody
targeting Dll4. Remaining Jag1-treated spheroids displayed
smaller and less complex glands, which contain pleomorphic cells
with bigger nuclei and less cytoplasm (Fig. 3h).
Absence of MFNG provides Notch ligand specificity. The
observation that adenoma initiation in the ApcMin/+ intestines
required Jag1-induced Notch signaling suggested that either Jag1
was the only Notch ligand expressed in the adenomas, or
adenoma-specific Notch1 was refractory to the induction by other
ligands such as Dll4. IF staining revealed that Jag1 and Dll4 were
present at comparable levels, and localized as expected at the
membrane of both normal organoids and adenoma-derived
spheroids (Fig. 4a). To explore the possibility that differential
expression of Fringe glycosyltransferase enzymes could explain a
shift from Dll- to Jag1-induced Notch signaling40, we examined
the protein levels of LFNG and MFNG by IF. We did not detect
any LFNG staining in our 3D intestinal cultures (not depicted). In
contrast, MFNG was detected in most of the non-transformed
organoid structures and notably absent in the ApcMin/+ adenoma
spheroids (Fig. 4a). IF examination of frozen (Supplementary
Fig. 3A) and paraffin-embedded ApcMin/+ intestinal sections
(Fig. 4b), using two different anti-MFNG antibodies, confirmed
that MFNG levels were significantly reduced in the adenoma
tissue, in clear contrast to the consistent staining observed in
adjacent normal crypts and at the base of the tumor area. MNFG
levels were also increased in tumors arising in the ApcMin/+ Jag1
KO intestines (Supplementary Fig. 3B) further suggesting that
MNFG levels regulate addition to Jag1. In the same direction,
non-transformed organoids carrying the Jag1lox/lox; β-actin-
Cre-ERT alleles, which express MFNG (not depicted), were
totally refractory to 4-OH-tamoxifen treatment (Fig. 4c, upper
panels). Efficiency of Jag1 (exon 4) deletion in the organoids
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following 4-OH-tamoxifen treatment was confirmed by PCR
(Fig. 4c, lower panel).
To experimentally test whether ectopic MFNG reverted
JAG1 addiction in the adenoma cells, we transduced ApcMin/+;
Jag1lox/lox;β-actin-Cre-ERT spheroids with retroviral control
(pMIG) or a vector codifying for MFNG, and then treated the
cultures with 5 μM 4-OH-tamoxifen to deplete adenoma cells
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expressing ectopic MFNG were morphologically indistinguishable
from the controls, although they were significantly protected from
the death induced by 4-OH-tamoxifen (Fig. 4d, e).
MFNG and Jagged1 expression predicts poor prognosis. We
then studied whether our results applied to human CRC. We
performed immunohistochemistry (IHC) analysis of Jag1 and
active ICN1 (Fig. 5a) in a cohort of 135 human adenomas
(Supplementary Table 1) and 242 carcinoma samples (Supple-
mentary Table 2). We found a significant correlation between the
levels of Jag1 and ICN1 in the adenoma samples (58 of 73 Jag1
high were ICN1 high; 80%, p= 0.0015) that was lost in the car-
cinomas (Supplementary Fig. 4A). Since ability of Notch to
respond to Jagged or Delta ligands in the adenomas is mostly
defined by MFNG expression, as we have found in the mouse
system, we reasoned that differences on MFNG levels might
explain these conflicting results. IF analysis of MFNG in our set of
samples (Fig. 5a and Supplementary Table 2) demonstrated that
MFNG levels were significantly divergent in the adenoma and
carcinoma samples (p < 0.0001) with MFNG primary lost in the
adenomas (46% of MFNG-negative adenomas compared with
17% of the carcinomas) (Supplementary Fig. 4B). More refined
analysis of ICN1 and Jag1 levels in the MFNG-positive and
-negative carcinoma samples demonstrated an inverse correlation
between Jag1 and ICN1 in the MFNG-positive group (p= 0.037)
whereas ICN1 detection was biased toward the JAG1 high group
in the absence of MFNG (nine out of 14 MFNG-negative and
ICN1-high tumors were JAG1 high) (Supplementary Table 2).
Importantly, we further analyzed Dll4 levels in a subset of CRC
samples and found that ten out of 11 tumors that were char-
acterized as ICN1 high/JAG1 low contained high levels of Dll4,
nine of them being MFNG positive (Supplementary Table 3),
further supporting that tumors expressing MFNG may induce
Notch1 through Dll4. Clinically relevant, inside the group of
patients carrying ICN1 high tumors, stratification according to
JAG1 and MFNG was predictive of disease outcome, being the
worst prognosis group that defined by JAG1 high and MFNG
negative (p= 0.0148, compared with the JAG1 low/MFNG
positive, and p= 0.04 compared with the unsorted population)
(Fig. 5b). In contrast, we did not observe any association between
JAG1 and/or MFNG levels and patient outcome in the Notch-
negative population (Supplementary Fig. 4C). In a public cohort
of 359 CRC tumors with both expression and clinical data
available (probed by TCGA41), patients in the Notch high group
with high MFNG expression do have better survival compared
with the low MFNG group, although differences did not achieve
statistical significance (Fig. 5c). Levels of MFNG in this subgroup
of tumors also determined the transcriptional status of several
Notch target genes such as NKD1, DLX3, EREG, EPHA4, or IL7R
(Fig. 5d), known to be relevant for cancer progression42–46.
Notably, MFNG levels were significantly lower in the tumors
included in the CRC subtype 247 (Supplementary Fig. 4D), which
is the most frequent and is characterized by a marked activation
of the WNT and MYC pathways.
Jag1 blocking antibodies reduce CRC growth in vivo. Finally,
we investigated the possibility that anti-Jag1 antibodies provide a
therapeutic benefit for human colorectal tumors. From a library
of primary human CRC developed as orthoxenografts in nude
mice, we selected a tumor that efficiently grew in 3D cultures and
lacked MFNG expression (Fig. 6a). A fragment of the tumor was
expanded subcutaneously in nude mice and after that, compar-
able tumor fragments were orthotopically implanted in the cecum
of 12 mice. When tumors were detectable by palpation, mice
were randomly separated in two groups of treatment. Animals
were treated twice a week by intraperitoneal injection with anti-
Jag1 (n= 6) or isotypic control antibody (n= 6), and 40 days
after initiating the treatments, animals were euthanized and
analyzed for the presence of tumors, either in the intestine or
associated to the wall of the peritoneum (scheme in Fig. 6b).
Treatment of the animals with the anti-Jag1 antibody significantly
reduced the size and weight of implanted tumors (Fig. 6c, d
and Supplementary Figure 5A), although we did not observed
a significant change in the number of peritoneal implants
between both groups (three animals with implants in the control
group and two animals in the treated group). Importantly,
IHC analysis of the tumors demonstrated that anti-Jag1
treatment imposed a significant increase in the extent of necro-
sis and fibrosis inside the tumor areas and a reduction in pro-
liferation in the residual tumor mass as determined by
Ki67 staining (Fig. 6e, f), which was not observed in the non-
transformed adjacent colonic tissue (Fig. 6g). Further indicating
that human CRC are highly addicted to Notch1 signaling, we
still detected ICN1 staining in the few growing areas of anti-
Jag1-treated tumors (Fig. 6h). Using an in vitro system of patient-
derived tumoroids (n= 5), we confirmed that anti-Jag1 treatment
was more effective in tumors carrying high levels of JAG1 and
low MFNG such as PDOXT005, PDOXT007, and PDOXT008
(Supplementary Fig. 5B).
Together, our findings demonstrate that mouse adenomas and
a particular subset of human CRC tumors require Jag1-mediated
Notch signaling for effective growing and to escape from
apoptosis. In this context, selective anti-Jag1 blocking antibodies
can be considered as plausible therapy for FAP disease but also
for the treatment of a selected group of CRC patients (see model
in Fig. 7).
Discussion
Strategies for therapeutically targeting Notch signaling in CRC
have suffered from numerous challenges. Clinical and pre-clinical
evaluations of GSIs have uncovered toxicities, including intestinal
goblet cell metaplasia associated with ISC loss. While intermittent
dosing or co-treatment with glucocorticoids may open a ther-
apeutic window48, selective antibody inhibitors of individual
Notch ligands or receptors provide an alternative therapeutic
strategy. Indeed, compared to dual inhibition of Notch1 and
Notch2, selective inhibition of either receptor alone minimized
intestinal toxicity22, consistent with functional redundancy of
these two receptors in intestinal homeostasis23. Unfortunately,
Fig. 2 Jag1 deficiency results in reduced levels of ISC markers in the tumor cells. a qRT-PCR to measure the mRNA levels of selected ISC markers in wild-
type and Jag1-deficient adenomas. The average and standard deviation (s.d.) of five tumors analyzed is represented. b In situ hybridization to determine the
expression pattern of c-Myc and different stem cell markers in tumor sections from the indicated genotypes. c Quantification of the percentage of tumors
containing detectable levels of the indicated genes as determined by ISH. A minimum of 20 tumors of each genotype was included in the analysis. d IF
analysis of LGR5 protein in normal or adenoma tissue in the indicated genotypes and quantification of 15 randomly selected areas (right panels). e IHC
analysis of the Paneth cell marker lysozyme and the absorptive marker carbonic anhydrase II (CAII) in tumors from the indicated genotypes. Graphs
represent the number of tumors expressing these markers in the indicated genotypes. Unpaired t-test, two-tailed, was used to determine the statistical
significance of the differences (***p < 0.001). Scale bars represent 75 μm
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such redundancy may be maintained in CRC29. Our discovery of
Jag1 dependence in ApcMin/+ adenomas raises the possibility of
an alternative strategy. We have found that intestinal epithelial
Jag1 deletion prevents ApcMin/+ tumor formation, reduces
expression of several ISC markers, and inhibits tumor spheroid
growth and re-passaging, a measure of TIC activity. In contrast,
Jag1 is dispensable for intestinal homeostasis, and systemic JAG1
inhibition does not cause goblet cell metaplasia. This is revolu-
tionary, since we could treat patients with JAG1-blocking anti-
body targeting exclusively the tumor cells and avoiding the strong
sides effects in the normal gut of FAP patients. Multiple lines of
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transcriptional program and other biological features with normal
ISCs49, but is responsible for tumor relapse, metastasis, and
chemotherapy resistance50–52. Our data suggest that β-catenin-
driven intestinal TIC population rely on JAG1.
When we then looked at human CRC, we found a mixed
pattern for JAG1 expression and no correlation between JAG1
and ICN1 levels. However, reduced MNFG levels determine a
distinctive addiction to JAG1 and might be valuable in stratifying
patient prognoses. Importantly, lower tumor expression of
MFNG significantly associated with poor CRC prognosis speci-
fically in the group of JAG1-high tumors. We propose that JAG1-
high/MFNG-low highlight a CRC subset that could benefit from
JAG1 therapeutic inhibitors. For example, MNFG is poorly
expressed in the CRC subtype 2, which is characterized by
marked activation of the WNT and MYC pathways. Taken
together, our findings provide a framework for considering a
Jag1-selective blocking antibody as a therapeutic candidate in
subsets of CRC patients, particularly those carrying ICN1-high/
MFNG-low tumors as well as those carrying germline Apc
mutations53. In fact, this possibility has been experimentally
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Fig. 4 Reduced levels of MFNG in intestinal adenomas impose Notch-ligand specificity. a IF analysis of the indicated proteins in organoid and spheroid
cultures embedded in paraffin. b IF analysis of MFNG in paraffin sections of two different ApcMin/+ intestinal adenomas. Representative images are
shown. c Representative images of non-transformed Jag1lox/lox;β-actin-Cre-ERT organoids left untreated or treated for 3 days with the indicated doses
of 4-OH-tamoxifen. RT-PCR of organoids treated as indicated showing the functional wild-type band, which is deleted upon treatment. d, e Jag1lox/lox;
β-actin-Cre-ERT adenoma cells were infected with a retroviral vector codifying for MFNG, then grown in matrigel to generate tumor spheroids, and treated
with 4-OH-tamoxifen for 48–72 h. Representative images (d) and quantification of six individual wells counted per condition (e). Bars represent mean
values ± standard error of the mean (s.e.m) from two independent experiments performed; p values were derived from an unpaired t-test, two-tailed.
Scale bars represent 50 μm in (a), 100 μm in (b), 75 μm in (c), and 200 μm in (d)
Fig. 3 Epithelial Jag1 is required for intestinal adenoma cells to grow in 3D cultures. a Representative FACS plot showing the sorted YFP+; ApcMin/+
adenoma cell population used in the spheroid cultures. b Sorted ApcMin/+;Jag1+/+;Villin-Cre+ or ApcMin/+;Jag1lox/lox;Villin-Cre+ intestinal adenomas cells
were seeded in the spheroid culture conditions. Graph shows the quantification from three biological replicates after 7 days in culture. c Representative
images of Jag1lox/+ or Jag1lox/lox;β-actin-Cre-ERT spheroids left untreated or treated for 4 days with 5 μM 4-OH-tamoxifen. d qRT-PCR analysis to
determine the expression levels of the indicated genes in Jag1lox/lox;β-actin-Cre-ERT spheroids at 0, 24, and 48 h of 5 μM tamoxifen (OH-T) treatment.
Values were normalized to the average value of β-2 microglobulin and Gapdh, and represented as percent of the vehicle-treated cultures. e IF analysis of the
indicated proteins and alcian blue staining in spheroid cultures embedded in paraffin following the indicated treatments (OH-T 5 μM, DAPT 2.5 μM).
f, g Graphs represent the quantification of the analysis shown in e. The average values from three biological replicates and standard deviation (s.d.) of the
mean are shown. In all experiments, bars represent mean values ± standard deviation of the mean; p values were derived from an unpaired t-test, two-
tailed. h Survival curves of ApcMin/+ spheroid cultures treated with the blocking anti-Jag1 or anti-DLL4 antibodies (left panel) and representative
hematoxylin and eosin (H&E) staining of anti-Jag1-treated spheroids (right panel). Scale bars represent 200 μm in (c) and 50 μm in (e) and (h)
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Methods
Animals. Jag1lox mice31 with lox sites flanking exon 4 (that codifies for the DSL
domain) were crossed with Lox-STOP-lox-ROSA26YFP (YFPlox)54 and Villin-Cre
and then with the ApcMin/+ mice (both from Jackson Laboratories). Mice were
genotyped by PCR and kept under pathogen-free conditions. The Animal Care
Committee of Generalitat de Catalunya and the Genentech Institutional Animal
Care and Use Committee (IACUC) approved all animal studies.
Antibodies. In the different analysis, we used primary antibodies against lysozyme
(1:5000, Dako A0099); GFP/YFP (1:200, Takara 632460); Ki67 (1:500, Novocastra
MM1); Myc (1:100, Santa Cruz sc-764); cleaved-caspase 3 (1:500, Cell Signaling
#9661); MFNG (1:100, Santa Cruz sc-8237, Ab#1 and Biorbyt orb157845, Ab#2);
Jagged1 (1:500, Santa Cruz sc-6011); Delta4 (1:1000, Abcam Ab7280); Muc2
(1:40055), CAII (1:2000, Rockland 200-401-136), Notch2 (1:500, Ab118824), and
active ICN1 (1:200, Cell Signaling #4147). Lgr5 (GPCR49, Ab75732). Blocking
anti-Dll4 antibody was provided by Genentech.
ISH. Murine intestinal samples were flushed gently with cold phosphate-buffered
saline and fixed overnight in 4% paraformaldehyde at room temperature. Samples
were then dehydrated, embedded in paraffin, and sectioned at 8 µm. After de-
paraffinization and rehydration, the samples were treated with 0.2 N HCl and
proteinase K (30 µg/mL). Samples were hybridized for 24 h at 65 °C. After washing,
blocking solution was added (Blocking reagent, Roche) and incubation with anti-
digoxigenin antibody was performed overnight at 4 °C. Next morning, samples
were washed and developed with NBT/BCIP (Roche). The RNA probes were
obtained from complementary DNA of mouse c-Myc, Sox9, Cd133, and Ascl2 and
were generated by in vitro transcription with a Digoxigenin RNA Labeling Kit
(Roche) according to the manufacturer’s instructions.
qRT-PCR analysis. Total RNA was extracted with the RNeasy Mini Kit (Qiagen)
and the RT-First Strand cDNA Synthesis Kit (Amersham Pharmacia Biotech, GE
Healthcare, Buckinghamshire, UK) was used to produce cDNA. qRT–PCR was
performed in LightCycler480 system using SYBR Green I Master Kit (Roche, Basel,
Switzerland). Primers used are detailed in Supplementary Table 4.
Mouse adenoma dissociation and cell sorting. Cell dissociation was performed
as previously described36,37. Briefly, pooled adenomas were incubated in 8 mM
EDTA for 20 min at 4 °C and the remaining un-soluble fraction treated with
0.4 mg/mL dispase and subsequently with 1.25 mg/mL collagenase 20 min each at
37 °C in agitation. Cell suspension was recovered by centrifugation at 1200 rpm
and suspended in 140 nM ROCK inhibitor (Y-27632, Sigma). We determined cell
viability by Trypan Blue dye exclusion or DAPI staining (VYSIS). Viable cells were
used for either direct cell culture, or sorted (based on YFP expression) in a
FACSAriaII (BD Biosciences) and collected in HBSS with antibiotics and 140 nm
ROCK inhibitor.
Mouse intestinal organoid and tumor spheroid cultures and staining.
Approximately 10–20 × 104 cells from either normal intestinal murine crypts
(organoids) or dissociated intestinal adenomas (spheroids) from ApcMin/+ mice
were seeded in 50 μL Matrigel (BD Biosciences) in 24-well plates. After poly-
merization, 500 μL of complete spheroid medium [DMEM/F12 plus penicillin (100
U/mL) and streptomycin (100 μg/mL) (Biological Industries); N2 and B27 (Invi-
trogen); 140 nM ROCK inhibitor, 100 ng/mL Noggin, and 20 ng/mL bFGF
(Peprotech); 100 ng/mL R-spondin (R&D Systems) and 50 ng/mL EGF (Sigma)]
was added. Cultures were maintained at 37 °C, 5% CO2 and medium changed every
2 days. According to standard protocols, we also added Wnt3 (R&D Systems) at
the start of the organoids cultures to facilitate their formation, and then removed it.
Notch inhibitor DAPT (Calbiochem) was used at 50 μM. Inducible deletion of Jag1
JAG1 lo; MFNG pos.
JAG1 lo; MFNG neg.
JAG1 hi; MFNG neg,
JAG1 hi; MFNG pos.
Unsorted
p = 0.0148


























NKD1 Up Ishikawa A. Mech Dev 2004 
DLX3 Up Viale-Bouroncle. BBRC 2014  
EREG Up Rodilla V. PNAS 2009 
EPHA4 Down Rodilla V. PNAS 2009 
IL7R Down González-García S. J ExpMed 2012
ASB2 Down Nie L. Cell Res 2012 
GFI1 Down Phelan JD. Plos Gen 2013 
CIITA Down Nakano N. JBC 2011 
CCR7 Down Yu VW. Genome Data 2015 
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IRF4 Down Zhao JL Cancer Res. 2016 
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Fig. 5 ICN1, JAG1, and MFNG levels predict CRC patient prognosis. a Representative images of Notch, JAG1, and MFNG staining in two different carcinoma
samples. Scale bars represent 75 μm. b, c Disease-free survival analyses (Kaplan–Meier curves) of the indicated groups of patients determined by IF
analysis of our cohort of patients (b) or from the TCGA CRC tumors in the subgroup (c) with high Notch1 expression that exhibit high (green) or low (blue)
expression of MFNG. d Genes previously identified as Notch targets in the indicated publications that were up- (Up) or downregulated (Down) in the
MFNG-low tumors compared to the MFNG-high
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Fig. 6 Treatment with antibody against Jag1 decreases human CRC tumor growth in vivo. a IF analysis of MFNG expression in the transplanted human
tumor and the adjacent normal colonic mucosa. b Scheme of the protocol used for testing the anti-tumor activity of anti-Jag1 antibody in vivo (10mg per
kg). c Photograph of the tumors recovered at the end of the experiment with the indicated treatments. d Median and standard deviation of tumor weight
in the animals from both groups of treatment. e Representative images of IHC analysis of cleaved-caspase 3 and the proliferation marker Ki67 in two
representative tumor sections from control and anti-jag1-treated animals and f average values and standard deviation of the data obtained from eight
independent 20× fields analyzed using the ImageJ program. Statistical significance of the differences between control and anti-Jag1-treated groups
was determined by t-test comparing. g IHC analysis with the indicated antibodies in normal adjacent tissue. h IF analysis of active Notch1 (ICN1) in
representative control and anti-Jag1-treated tumors. Scale bars represent 75 μm in (a), 100 μm (cleaved-caspase 3) and 50 μm (Ki67) in (e), 200 μm
in (g), and 75 μm and 25 μm (magnification) in (h)
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in the preformed ApcMin/+;Jag1lox/lox;β-actin-Cre-ERT spheroids was achieved by
treating the cultures with the indicated doses of 4-hydroxytamoxifen up to 72 h.
For whole-mount immunostaining analysis, organoids and spheroids were fixed
with 4% paraformaldehyde and permeabilized with 0.3% Triton X-100 (Pierce).
Primary antibodies were incubated overnight. Secondary antibodies were Alexa
Fluor from Molecular Probes and were incubated for 2 h at room temperature
at a 1:1000 dilution. Slides were mounted in VectaShield with DAPI (Vector).
Patient-derived CRC xenografts and tumoroids. Fragments of primary human
colorectal tumors obtained from MARbiobank with the informed consent of
patients and following all recommendations of Hospital del Mar’ Ethics
Committee, the Spanish regulations, and the Helsinki declaration’s Guide were
transplanted and expanded in the cecum of nude mice as orthoxenografts. For
tumoroids generation, xenografted tumors were disaggregated in 1 mg/mL
collagenase II (Sigma) and 20 µg/mL hyaluronidase (Sigma), filtered in 100 µm cell
strainer, and seeded in Matrigel (BD Biosciences) as previously described37.
Tumoroid viability assays. A total of 600 single tumoroid cells were plated in 96-
well plates in Matrigel. After 4 days in culture, the growing tumoroids were treated
with Jag1 or Dll4 blocking antibodies for 72 h at the indicated concentrations. Cell
viability was determined using the CellTiter-Glo® 3D Cell Viability Assay (Pro-
mega) following manufacturer’s instructions in an Orion II multiplate lumin-
ometer (Berthold detection systems). All the experiments were conducted in
triplicate.
Retroviral transduction of mouse intestinal tumoroids. Mouse intestinal
tumoroids grown in Matrigel were mechanically disrupted using a 30G needle.
Clumps were collected by centrifugation at 900×g for 5 min and cells were further
individualized in trypsin for 5 min at 37 °C. Cellular suspension was then cen-
trifuged at 900×g for 5 min, resuspended in 250 µL of retroviral solution containing
Polybrene, Y-27632 and either pMIG-ires-GFP control or the pMIEV-Mfng-ires-
GFP vector (provided by Dr. Cynthia Guidos) and seeded in 48-well plates. The
whole plate was then centrifuged at 600×g at 32 °C for 1 h and incubated for 6 h at
37 °C. Finally, comparable numbers of control or Mfng-transduced cells were
plated in Matrigel.
Human colorectal samples. Formalin-fixed, paraffin-embedded tissue blocks of
colorectal tumors were obtained from Parc de Salut MAR Biobank (MARBiobanc),
Barcelona. Multiple areas of invasive carcinoma, adenomas, and normal adjacent
mucosa from the same surgical sample were identified on corresponding
hematoxylin–eosin-stained slides. Tissue blocks were transferred to a recipient
“master” block using a Tissue Microarrayer. A minimum of 2–3 cores from the
same tumor was included in the array and each core was 0.6 mm wide spaced,
0.7–0.8 mm apart. A pathologist specialist in the gastrointestinal tract (M.I.)
performed the histological characterization of human intestinal specimens.
IHC and IF. Intestinal samples or organoid pellets included in the paraffin blocks
were sectioned at 4 µm and 2.5 µm, respectively. After deparaffinization and
rehydration, endogenous peroxidase activity was quenched (20 min, 1.5% H2O2)
and antigen retrieval was performed depending on the antibody. All primary
antibodies were diluted in PBS containing 0.05% BSA and incubated overnight at 4
°C, unless otherwise indicated. Sections were then incubated with specific horse-
radish peroxidase-labeled secondary antibody (DAKO Envision), and staining was
developed using diaminobenzidine peroxidase substrate kit (DakoCytomation) or
Tyramide Signal Amplification System (Perkin Elmer). BrdU (1:250, abcam
ab6326) was incubated 2 h at room temperature and the secondary antibody
system used was a biotinylated anti-rat antibody (Dako, E0468) 1 h at room
temperature followed by the Vectastain ABC kit (Vector, PK6100). Staining was
developed as described above. Alcian Blue and H&E staining were performed using
standard procedures.
Image analysis and statistical methods. IHC of intestinal sections were observed
in an Olympus BX61 microscope and blindly assessed as low (0–1+) or high (2–3
+) in the case of JAG1 and Notch, or negative/positive for MFNG by two
independent researchers. Images were taken using the cellSens Digital Imaging
software. IF images of intestinal sections and the organoids and spheroids were
taken by confocal microscopy with a Leica SP5 TCS upright microscope and the
Leica Application Suite Advanced Fluorescence software. Kaplan–Meier survival
curves were generated using the Prism software and comparisons made using the
Log-rank (Mantel–Cox) two-tailed test.
Analysis of public database. Normalized expression (RNA-seq RPKMs) data of
colorectal tumors in the TCGA cohort and clinical data of patients of the same
cohort were downloaded from synapse (syn300013) and TCGA Data Portal
(https://tcga-data.nci.nih.gov/tcga/), respectively. These data were used for the
analysis of the expression levels of Notch1, MFNG, and known targets of the Notch
pathway. To carry out these analyses, we first selected the half of the CRC cohort
with higher expression of Notch1, and then separated this subgroup of tumors
in two halves according to their expression of MFNG.
Data availability. Gene expression data of TCGA colorectal tumors used in this
study are available at http://firebrowse.org/?cohort= COADREAD.
















Fig. 7 Model representing the differential requirement for Jag1 in the normal and transformed intestinal epithelial cells. As shown in the figure, MFNG in
normal intestinal stem cells glycosylate Notch1 thus favoring its activation mediated by the Dll4 ligand that is localized in the adjacent (Paneth) cells.
In contrast, non-glycosylated Notch1 present in the MFNG-negative tumor cells cannot respond to Dll4 leading to Jag1, which makes them addicted to
Jag1-dependent Notch signaling
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